SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sanofi India soars on reporting 33% jump in Q2 net profit

25 Jul 2016 Evaluate

Sanofi India is currently trading at Rs. 4620.50, up by 120.85 points or 2.69% from its previous closing of Rs. 4499.65 on the BSE.

The scrip opened at Rs. 4646.45 and has touched a high and low of Rs. 4650.00 and Rs. 4600.00 respectively. So far 516 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 4770.00 on 04-Jul-2016 and a 52 week low of Rs. 3676.00 on 24-Jul-2015.

Last one week high and low of the scrip stood at Rs. 4701.00 and Rs. 4450.00 respectively. The current market cap of the company is Rs. 10681.14 crore.

The promoters holding in the company stood at 60.40%, while Institutions and Non-Institutions held 29.40% and 10.20% respectively.

Sanofi India has registered a surge of 32.87% in its net profit at Rs 85.30 crore for the second quarter ended June 30, 2016 as compared to Rs 64.20 crore for the same quarter in the previous year. Total income of the company increased by 11.58% at Rs 624.40 crore for the quarter ended June 30, 2016 as compared Rs 559.60 crore for the corresponding quarter previous year.

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets and animal health.

Sanofi India Share Price

3410.60 55.15 (1.64%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: